

Sten Madsbad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4797501/publications.pdf>

Version: 2024-02-01

305
papers

17,557
citations

15504

65
h-index

17105

122
g-index

319
all docs

319
docs citations

319
times ranked

14983
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β -cell function in type 2 diabetes: a parallel-group study. <i>Lancet, The</i> , 2002, 359, 824-830.	13.7	1,207
2	Angiotensin-Receptor Blockade versus Convertingâ€Enzyme Inhibition in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2004, 351, 1952-1961.	27.0	844
3	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3717-3723.	3.6	767
4	The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on β -Cell Sensitivity in Type 2 and Nondiabetic Subjects. <i>Diabetes</i> , 2003, 52, 380-386.	0.6	513
5	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , 2017, 389, 1399-1409.	13.7	502
6	Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1608-1610.	8.6	415
7	Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. <i>Regulatory Peptides</i> , 2003, 114, 115-121.	1.9	360
8	Reduced Incretin Effect in Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 1951-1959.	0.6	297
9	Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211). <i>Diabetes Care</i> , 2004, 27, 1335-1342.	8.6	296
10	Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β -Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2013, 62, 3044-3052.	0.6	262
11	Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. <i>Genome Medicine</i> , 2016, 8, 67.	8.2	260
12	Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 152-164.	11.4	248
13	Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, S251-S257.	8.6	233
14	Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2112-2119.	2.8	225
15	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3717-3723.	3.6	224
16	Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. <i>Diabetes</i> , 2014, 63, 1725-1737.	0.6	220
17	Review of headâ€toâ€head comparisons of glucagonâ€like peptideâ€1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 317-332.	4.4	211
18	Proteomics reveals the effects of sustained weight loss on the human plasma proteome. <i>Molecular Systems Biology</i> , 2016, 12, 901.	7.2	188

#	ARTICLE	IF	CITATIONS
19	Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 1906-1913.	13.7	173
20	Early Differential Defects of Insulin Secretion and Action in 19-Year-Old Caucasian Men Who Had Low Birth Weight. <i>Diabetes</i> , 2002, 51, 1271-1280.	0.6	172
21	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. <i>New England Journal of Medicine</i> , 2021, 384, 1719-1730.	27.0	171
22	Decreased Insulin Removal Contributes to Hyperinsulinemia in Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1981, 53, 618-621.	3.6	170
23	Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbA1c levels, but is not acutely affected by food intake. <i>European Journal of Endocrinology</i> , 2006, 155, 485-493.	3.7	168
24	Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. <i>European Journal of Clinical Investigation</i> , 1982, 12, 81-85.	3.4	167
25	Increased expression of TNF- α , IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 285, E1072-E1080.	3.5	165
26	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. <i>Diabetologia</i> , 2014, 57, 1919-1926.	6.3	156
27	Practical Clinical Value of the C-peptide Response to Glucagon Stimulation in the Choice of Treatment in Diabetes Mellitus. <i>Acta Medica Scandinavica</i> , 1981, 210, 153-156.	0.0	154
28	Glucagon-like peptide-1, glucose homeostasis and diabetes. <i>Trends in Molecular Medicine</i> , 2008, 14, 161-168.	6.7	152
29	Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 708-714.	1.2	144
30	Incretin-Based Therapies. <i>Diabetes Care</i> , 2009, 32, S223-S231.	8.6	143
31	Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β -Cell Function. <i>Diabetes Care</i> , 2011, 34, 1463-1468.	8.6	143
32	Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β -Cell Function. <i>Diabetes</i> , 2011, 60, 1599-1607.	0.6	131
33	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 221-232.	11.4	127
34	Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans. <i>Diabetes</i> , 2010, 59, 2160-2163.	0.6	126
35	Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 883-888.	8.6	125
36	G-allele of Intronic rs10830963 in <i>MTNR1B</i> Confers Increased Risk of Impaired Fasting Glycemia and Type 2 Diabetes Through an Impaired Glucose-Stimulated Insulin Release. <i>Diabetes</i> , 2009, 58, 1450-1456.	0.6	125

#	ARTICLE	IF	CITATIONS
37	Altered Skeletal Muscle Fiber Composition and Size Precede Whole-Body Insulin Resistance in Young Men with Low Birth Weight. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1530-1534.	3.6	122
38	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2909-2917.	3.6	116
39	Studies of the Pro12Ala Polymorphism of the PPAR- γ Gene in the Danish MONICA Cohort: Homozygosity of the Ala Allele Confers a Decreased Risk of the Insulin Resistance Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3989-3992.	3.6	112
40	Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 463-477.	4.7	108
41	Effect of porcine gastric inhibitory polypeptide on β -cell function in type I and type II diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 677-682.	3.4	107
42	Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion. <i>Diabetes Care</i> , 2010, 33, 375-377.	8.6	105
43	Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. <i>Diabetologia</i> , 2013, 56, 2250-2254.	6.3	100
44	CRP and suPAR are differently related to anthropometry and subclinical organ damage. <i>International Journal of Cardiology</i> , 2013, 167, 781-785.	1.7	99
45	Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. <i>Gastroenterology</i> , 2019, 156, 1627-1641.e1.	1.3	99
46	A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2019, 62, 2066-2078.	6.3	98
47	Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E324-E330.	3.5	92
48	Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. <i>Diabetes Care</i> , 2015, 38, 2250-2257.	8.6	91
49	Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4679-4687.	3.6	89
50	Improvements in Glucose Metabolism Early After Gastric Bypass Surgery Are Not Explained by Increases in Total Bile Acids and Fibroblast Growth Factor 19 Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E396-E406.	3.6	89
51	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. <i>Cell Metabolism</i> , 2018, 28, 23-32.e3.	16.2	88
52	Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 491-499.	2.5	85
53	Pleiotropic Effects of GIP on Islet Function Involve Osteopontin. <i>Diabetes</i> , 2011, 60, 2424-2433.	0.6	83
54	Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. <i>Diabetologia</i> , 2013, 56, 2679-2687.	6.3	82

#	ARTICLE	IF	CITATIONS
55	Altered Fat Tissue Distribution in Young Adult Men Who Had Low Birth Weight. <i>Diabetes Care</i> , 2005, 28, 151-153.	8.6	81
56	Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. <i>Human Reproduction</i> , 2008, 23, 2113-2121.	0.9	80
57	Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. <i>Cell Systems</i> , 2018, 7, 601-612.e3.	6.2	80
58	Altered PI3-Kinase/Akt Signalling in Skeletal Muscle of Young Men with Low Birth Weight. <i>PLoS ONE</i> , 2008, 3, e3738.	2.5	76
59	Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance. <i>Diabetes</i> , 2013, 62, 2088-2094.	0.6	75
60	Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 766-780.	11.4	74
61	Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations – Role of Carbohydrate and Energy Availability. <i>Diabetes</i> , 2018, 67, 2129-2136.	0.6	74
62	GLP-1: physiological effects and potential therapeutic applications. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 994-1003.	4.4	73
63	Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY36. <i>European Journal of Endocrinology</i> , 2016, 174, 775-784.	3.7	72
64	Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. <i>Diabetes Care</i> , 2017, 40, 117-124.	8.6	72
65	Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity. <i>Clinical Endocrinology</i> , 2006, 64, 169-178.	2.4	67
66	Short-term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: a randomized open-label crossover trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1479-1484.	4.4	67
67	Metabolic and Cardiovascular Responses to Epinephrine in Diabetic Autonomic Neuropathy. <i>New England Journal of Medicine</i> , 1987, 317, 421-426.	27.0	66
68	Increased Hepatic Insulin Clearance After Roux-en-Y Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1066-E1071.	3.6	66
69	On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E614-E621.	3.5	64
70	Reduced skeletal muscle mitochondrial respiration and improved glucose metabolism in nondiabetic obese women during a very low calorie dietary intervention leading to rapid weight loss. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1145-1152.	3.4	63
71	Postoperative Morbidity and Mortality in Type-2 Diabetics After Fast-Track Primary Total Hip and Knee Arthroplasty. <i>Anesthesia and Analgesia</i> , 2015, 120, 230-238.	2.2	62
72	Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E535-E544.	3.5	62

#	ARTICLE	IF	CITATIONS
73	Effect of Hyperglycemia on Mitochondrial Respiration in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1372-1378.	3.6	61
74	Whole Body Clearance of Norepinephrine. THE SIGNIFICANCE OF ARTERIAL SAMPLING AND OF SURGICAL STRESS. Journal of Clinical Investigation, 1983, 71, 500-505.	8.2	61
75	Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. Diabetes Care, 2017, 40, 132-135.	8.6	60
76	Adipose expression of adipocytokines in women with polycystic ovary syndrome. Fertility and Sterility, 2012, 98, 235-241.	1.0	59
77	Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surgery for Obesity and Related Diseases, 2016, 12, 1236-1242.	1.2	59
78	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E505-E514.	3.5	56
79	Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism: Clinical and Experimental, 2003, 52, 885-894.	3.4	55
80	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regulatory Peptides, 2007, 144, 123-130.	1.9	55
81	Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?. Journal of Diabetes and Its Complications, 2016, 30, 374-385.	2.3	54
82	Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes, Obesity and Metabolism, 2021, 23, 1397-1401.	4.4	53
83	Dissociation between Fat-Induced Insulin Resistance and Proximal Insulin Signaling in Skeletal Muscle in Men at Risk for Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1301-1311.	3.6	52
84	The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regulatory Peptides, 2006, 137, 168-172.	1.9	52
85	Liraglutide Effect and Action in Diabetes (LEAD, C) trial. Expert Review of Endocrinology and Metabolism, 2009, 4, 119-129.	2.4	50
86	Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. American Journal of Clinical Nutrition, 2015, 102, 600-607.	4.7	50
87	Molecular Mechanisms in Skeletal Muscle Underlying Insulin Resistance in Women Who Are Lean With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1841-1854.	3.6	50
88	No Response of Pancreatic Hormones to Hypoglycemia in Diabetic Autonomic Neuropathy*. Journal of Clinical Endocrinology and Metabolism, 1982, 54, 815-819.	3.6	49
89	Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. Current Diabetes Reviews, 2009, 5, 266-275.	1.3	49
90	GLP-1 as a Mediator in the Remission of Type 2 Diabetes After Gastric Bypass and Sleeve Gastrectomy Surgery. Diabetes, 2014, 63, 3172-3174.	0.6	49

#	ARTICLE	IF	CITATIONS
91	Studies of the Association of Arg72Pro of Tumor Suppressor Protein p53 with Type 2 Diabetes in a Combined Analysis of 55,521 Europeans. PLoS ONE, 2011, 6, e15813.	2.5	49
92	Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in Î²-cell function. Metabolism: Clinical and Experimental, 2003, 52, 1343-1353.	3.4	48
93	K _{ATP} Channel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 603-608.	3.6	48
94	Bariatric Surgery - Effects on Obesity and Related co-Morbidities. Current Diabetes Reviews, 2014, 10, 208-214.	1.3	48
95	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. Cardiovascular Diabetology, 2016, 15, 105.	6.8	48
96	IRS-1 Serine Phosphorylation and Insulin Resistance in Skeletal Muscle From Pancreas Transplant Recipients. Diabetes, 2006, 55, 785-791.	0.6	47
97	Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 1241-1257.	7.3	47
98	Sulfatide Controls Insulin Secretion by Modulation of ATP-sensitive K ⁺ -Channel Activity and Ca ²⁺ -Dependent Exocytosis in Rat Pancreatic Î²-Cells. Diabetes, 2002, 51, 2514-2521.	0.6	46
99	In vivo and in vitro degradation of peptide YY ₃₆ to inactive peptide YY ₃₄ in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R866-R874.	1.8	46
100	Effect of Glucagon-Like Peptide-1 on Î±- and Î²-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2492-2496.	3.6	45
101	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone, 2019, 125, 178-185.	2.9	45
102	Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism: Clinical and Experimental, 2009, 58, 586-593.	3.4	44
103	Insulin secretory reserve in insulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. European Journal of Endocrinology, 1980, 95, 359-363.	3.7	43
104	Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis, 2019, 288, 60-66.	0.8	43
105	The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 410-419.	1.2	42
106	Enhanced insulin signaling in human skeletal muscle and adipose tissue following gastric bypass surgery. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R510-R524.	1.8	42
107	Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes. Diabetology and Metabolic Syndrome, 2015, 7, 12.	2.7	42
108	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. Diabetes, 2016, 65, 239-254.	0.6	41

#	ARTICLE	IF	CITATIONS
109	C-reactive protein, insulin resistance and risk of cardiovascular disease: a population-based study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 594-598.	2.8	40
110	Overnight glucose control in people with type 1 diabetes. <i>Biomedical Signal Processing and Control</i> , 2018, 39, 503-512.	5.7	40
111	Insulin Secretion and Cellular Glucose Metabolism after Prolonged Low-Grade Intralipid Infusion in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2775-2783.	3.6	39
112	No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis. <i>Diabetes Care</i> , 2003, 26, 2581-2587.	8.6	39
113	A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients. <i>British Journal of Nutrition</i> , 2018, 119, 910-917.	2.3	39
114	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 313-324.	11.4	39
115	Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor β coactivator 1 (PGC-1 β) gene in Danish subjects with the metabolic syndrome. <i>Diabetes Research and Clinical Practice</i> , 2005, 67, 175-179.	2.8	38
116	Tumor necrosis factor α is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 175-182.	3.4	38
117	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease. <i>Journal of Hypertension</i> , 2017, 35, 1070-1078.	0.5	37
118	Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2022, 65, 506-517.	6.3	37
119	Hyponatremia and hyperkalemia in relation to hyperglycemia in insulin-treated diabetic out-patients. <i>Clinica Chimica Acta</i> , 1982, 120, 243-250.	1.1	36
120	Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. <i>Journal of Medical Virology</i> , 2005, 77, 29-38.	5.0	36
121	Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1910-1914.	8.6	35
122	Effect of large weight reductions on measured and estimated kidney function. <i>BMC Nephrology</i> , 2017, 18, 52.	1.8	34
123	Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. <i>Human Reproduction</i> , 2022, 37, 1414-1422.	0.9	34
124	Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic β -cells. <i>European Journal of Endocrinology</i> , 2005, 152, 103-112.	3.7	32
125	Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-Y gastric bypass. <i>Physiological Reports</i> , 2017, 5, e13140.	1.7	32
126	Normal Secretion and Action of the Gut Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Young Men with Low Birth Weight. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4912-4919.	3.6	31

#	ARTICLE	IF	CITATIONS
127	Treatment of type 2 diabetes with incretin-based therapies. <i>Lancet</i> , The, 2009, 373, 438-439.	13.7	31
128	Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2367-2375.	3.6	31
129	The insulin-resistant phenotype of polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2010, 94, 1052-1058.	1.0	31
130	Semaglutide seems to be more effective the other GLP-1Ras. <i>Annals of Translational Medicine</i> , 2017, 5, 505-505.	1.7	31
131	Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men. <i>Physiological Reports</i> , 2017, 5, e13073.	1.7	31
132	Genetic and Nongenetic Regulation of CAPN10 mRNA Expression in Skeletal Muscle. <i>Diabetes</i> , 2005, 54, 3015-3020.	0.6	30
133	Model-Based Closed-Loop Glucose Control in Type 1 Diabetes: The DiaCon Experience. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 1255-1264.	2.2	30
134	Prenatal exposure to persistent organochlorine pollutants is associated with high insulin levels in 5-year-old girls. <i>Environmental Research</i> , 2015, 142, 407-413.	7.5	30
135	Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. <i>BMJ Open</i> , 2016, 6, e008376.	1.9	30
136	Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy. <i>Diabetes</i> , 2005, 54, 3474-3483.	0.6	29
137	Emerging drugs for the treatment of obesity. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 87-99.	2.4	29
138	Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1-Renal Axis in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2509-2519.	3.6	29
139	Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 492-500.	4.4	29
140	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. <i>Cell Reports</i> , 2017, 21, 1452-1460.	6.4	28
141	The impact of gastric bypass surgery on sex hormones and menstrual cycles in premenopausal women. <i>Gynecological Endocrinology</i> , 2017, 33, 160-163.	1.7	28
142	Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo-controlled, double-blind, parallel-group study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 773-782.	4.4	28
143	Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. <i>Diabetologia</i> , 2015, 58, 920-928.	6.3	27
144	Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G661-G672.	3.4	27

#	ARTICLE	IF	CITATIONS
145	Non-insulin pharmacological therapies for treating type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 947-960.	1.8	25
146	Effect of bariatric surgery on plasma GDF15 in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E615-E621.	3.5	25
147	Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine. <i>International Journal of Obesity</i> , 2020, 44, 1859-1871.	3.4	25
148	Changes in Hematology and Calcium Metabolism After Gastric Bypass Surgery—a 2-Year Follow-Up Study. <i>Obesity Surgery</i> , 2015, 25, 1647-1652.	2.1	24
149	Updates in weight loss surgery and gastrointestinal peptides. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 21-28.	2.3	24
150	Plasma testosterone and androstenedione in insulin dependent patients at time of diagnosis and during the first year of insulin treatment. <i>European Journal of Endocrinology</i> , 1982, 100, 406-409.	3.7	23
151	Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. <i>Contraception</i> , 1999, 60, 337-344.	1.5	23
152	Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of β^2 -cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2004, 287, E677-E685.	3.5	23
153	Skeletal muscle mitochondrial function in polycystic ovarian syndrome. <i>European Journal of Endocrinology</i> , 2011, 165, 631-637.	3.7	23
154	Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity. <i>Obesity Facts</i> , 2017, 10, 633-647.	3.4	23
155	beta-Cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. <i>Clinical Endocrinology</i> , 2005, 62, 354-361.	2.4	22
156	Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 296-304.	4.7	22
157	Nonalcoholic Fatty Liver Disease Impairs the Liver's Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. <i>Hepatology Communications</i> , 2020, 4, 1610-1623.	4.3	22
158	Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. <i>International Journal of Clinical Practice</i> , 2021, 75, e13731.	1.7	22
159	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. <i>Cell Reports Medicine</i> , 2020, 1, 100006.	6.5	22
160	Metformin monotherapy for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2020, 2020, CD012906.	2.8	21
161	Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. <i>Journal of Clinical Medicine</i> , 2021, 10, 3783.	2.4	21
162	Desaturation of Skeletal Muscle Structural and Depot Lipids in Obese Individuals during a Very-Low-Calorie Diet Intervention. <i>Obesity</i> , 2007, 15, 117-117.	3.0	20

#	ARTICLE	IF	CITATIONS
163	LY2605541—A Preferential Hepato-Specific Insulin Analogue. <i>Diabetes</i> , 2014, 63, 390-392.	0.6	20
164	No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2016, 26, 2263-2267.	2.1	20
165	Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 850-857.	4.4	19
166	Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 303-314.	4.4	19
167	The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1383-1391.	1.2	19
168	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. <i>Regulatory Peptides</i> , 2010, 163, 96-101.	1.9	18
169	Reduction in cardiovascular risk factors and insulin dose, but no beta-cell regeneration 1 year after Roux-en-Y gastric bypass in an obese patient with type 1 diabetes: A case report. <i>Obesity Research and Clinical Practice</i> , 2013, 7, e269-e274.	1.8	18
170	Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 832-839.	1.5	17
171	Effects of Everyday Life Events on Glucose, Insulin, and Glucagon Dynamics in Continuous Subcutaneous Insulin Infusion-Treated Type 1 Diabetes: Collection of Clinical Data for Glucose Modeling. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 210-217.	4.4	17
172	S100A8/A9 (Calprotectin), Interleukin-6, and C-Reactive Protein in Obesity and Diabetes before and after Roux-en-Y Gastric Bypass Surgery. <i>Obesity Facts</i> , 2017, 10, 386-395.	3.4	17
173	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1429-1432.	1.5	17
174	Genetic Determinants of Weight Loss After Bariatric Surgery. <i>Obesity Surgery</i> , 2019, 29, 2554-2561.	2.1	17
175	Effects of carbohydrate restriction on postprandial glucose metabolism, β -cell function, gut hormone secretion, and satiety in patients with Type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E7-E18.	3.5	17
176	The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1448-1458.	2.8	17
177	Studies of association between LPIN1 variants and common metabolic phenotypes among 17,538 Danes. <i>European Journal of Endocrinology</i> , 2010, 163, 81-87.	3.7	16
178	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 734-738.	4.4	16
179	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2752-2762.	4.4	16
180	Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. <i>European Journal of Internal Medicine</i> , 2012, 23, 132-136.	2.2	15

#	ARTICLE	IF	CITATIONS
181	The Impact of Nocturnal Hypoglycemia on Sleep in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 2151-2157.	8.6	15
182	Liraglutide for treating type 1 diabetes. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 579-590.	3.1	15
183	Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 312, R797-R805.	1.8	15
184	Preoperative High-Dose Methylprednisolone and Glycemic Control Early After Total Hip and Knee Arthroplasty. <i>Anesthesia and Analgesia</i> , 2018, 127, 906-913.	2.2	15
185	Augmented GLP-1 Secretion as Seen After Gastric Bypass May Be Obtained by Delaying Carbohydrate Digestion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3233-3244.	3.6	15
186	The importance of plasma free insulin and counterregulatory hormones for the recovery of blood glucose following hypoglycaemia in Type 1 diabetics. <i>European Journal of Endocrinology</i> , 1985, 108, 224-230.	3.7	14
187	Effects of Roux-en-Y Gastric Bypass on Fasting and Postprandial Levels of the Inflammatory Markers YKL-40 and MCP-1 in Patients with Type 2 Diabetes and Glucose Tolerant Subjects. <i>Journal of Obesity</i> , 2013, 2013, 1-10.	2.7	14
188	Retinal characteristics during 1 year of insulin pump therapy in type 1 diabetes: a prospective, controlled, observational study. <i>Acta Ophthalmologica</i> , 2016, 94, 540-547.	1.1	14
189	Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 1101-1111.	2.2	14
190	Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2012-2016.	4.4	14
191	Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. <i>Nature Communications</i> , 2022, 13, .	12.8	14
192	Intramyocellular triglyceride content in man, influence of sex, obesity and glycaemic control. <i>European Journal of Endocrinology</i> , 2009, 161, 57-64.	3.7	13
193	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E284-E291.	3.5	13
194	Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 621-632.	3.1	13
195	Mechanisms Underlying Absent Training-Induced Improvement in Insulin Action in Lean, Hyperandrogenic Women With Polycystic Ovary Syndrome. <i>Diabetes</i> , 2020, 69, 2267-2280.	0.6	13
196	Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy. <i>International Journal of Obesity</i> , 2020, 44, 1872-1883.	3.4	13
197	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E956-E964.	3.5	13
198	Impact of prolonged fasting on insulin secretion, insulin action, and hepatic versus whole body insulin secretion disposition indices in healthy young males. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 320, E281-E290.	3.5	13

#	ARTICLE	IF	CITATIONS
199	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. <i>Pharmacological Research</i> , 2022, 176, 106058.	7.1	13
200	Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic Human Immunodeficiency Virus-infected patients. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1565-1573.	3.4	12
201	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. <i>BMJ Open</i> , 2015, 5, e007791-e007791.	1.9	12
202	Major rapid weight loss induces changes in cardiac repolarization. <i>Journal of Electrocardiology</i> , 2016, 49, 467-472.	0.9	12
203	Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects. <i>Nutrients</i> , 2018, 10, 1285.	4.1	12
204	The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e11-e19.	3.6	12
205	Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. <i>European Journal of Endocrinology</i> , 2022, 186, 687-700.	3.7	12
206	Genetic Variation in the Natriuretic Peptide System, Circulating Natriuretic Peptide Levels, and Blood Pressure: An Ambulatory Blood Pressure Study. <i>American Journal of Hypertension</i> , 2012, 25, 1095-1100.	2.0	11
207	Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. <i>BMJ Open</i> , 2014, 4, e005942-e005942.	1.9	11
208	Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial. <i>BMJ Open</i> , 2016, 6, e008377.	1.9	11
209	Gastric bypass surgery reveals independency of obesity and diabetes melitus type 2. <i>BMC Endocrine Disorders</i> , 2016, 16, 59.	2.2	11
210	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. <i>BMJ Open</i> , 2019, 9, e031431.	1.9	11
211	Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 150.	6.8	11
212	Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention. <i>Lipids in Health and Disease</i> , 2009, 8, 34.	3.0	10
213	Relationship between common lipoprotein lipase gene sequence variants, hyperinsulinemia, and risk of ischemic heart disease: A population-based study. <i>Atherosclerosis</i> , 2010, 211, 506-511.	0.8	10
214	Soluble urokinase plasminogen activator receptor, <sc>C</sc>â€reactive protein and triglyceride are associated with heart rate variability in nonâ€diabetic Danes. <i>European Journal of Clinical Investigation</i> , 2013, 43, 457-468.	3.4	10
215	Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study. <i>Diabetes Care</i> , 2018, 41, 797-806.	8.6	10
216	Changes in Serum Sphingomyelin After Roux-en-Y Gastric Bypass Surgery Are Related to Diabetes Status. <i>Frontiers in Endocrinology</i> , 2018, 9, 172.	3.5	10

#	ARTICLE	IF	CITATIONS
217	Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 42.	2.7	10
218	Bariatric surgeryâ€”which procedure is the optimal choice?. <i>Lancet, The</i> , 2019, 393, 1263-1264.	13.7	10
219	Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 401-407.	1.2	10
220	Reduction of oxidative stress on DNA and RNA in obese patients after Roux-en-Y gastric bypass surgeryâ€”An observational cohort study of changes in urinary markers. <i>PLoS ONE</i> , 2020, 15, e0243918.	2.5	10
221	Sham Feeding Increases Glucose Tolerance by a Mechanism Independent of Insulin Secretion in Normal Subjects. <i>Digestion</i> , 1995, 56, 253-258.	2.3	9
222	Insulin secretion rates estimated by two mathematical methods in pancreas-kidney transplant recipients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 274, E716-E725.	3.5	9
223	Under-reporting of adverse effects of tesofensine. <i>Lancet, The</i> , 2013, 382, 127.	13.7	9
224	The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial. <i>Lipids in Health and Disease</i> , 2018, 17, 295.	3.0	9
225	Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2017-2026.	4.4	9
226	In nondiabetic, human immunodeficiency virusâ€”infected patients with lipodystrophy, hepatic insulin extraction and posthepatic insulin clearance rate are decreased in proportion to insulin resistance. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 171-179.	3.4	8
227	Growth factors, glucose and insulin kinetics after low dose growth hormone therapy in HIV-lipodystrophy. <i>Journal of Infection</i> , 2006, 52, 389-398.	3.3	8
228	Factors of Importance for Residual Betaâ€”cell Function in Type I Diabetes Mellitus. <i>Acta Medica Scandinavica</i> , 1983, 213, 61-67.	0.0	8
229	Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 377-387.	1.5	8
230	The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. <i>Clinical Nutrition ESPEN</i> , 2020, 39, 46-52.	1.2	8
231	Metabolic improvement after gastric bypass correlates with changes in IGF-regulatory proteins stanniocalcin-2 and IGFBP-4. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154886.	3.4	8
232	Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study. <i>Bone</i> , 2021, 152, 116065.	2.9	8
233	Circulating sex hormones and gene expression of subcutaneous adipose tissue oestrogen and alpha-adrenergic receptors in HIV-lipodystrophy: implications for fat distribution. <i>Clinical Endocrinology</i> , 2007, 67, 250-258.	2.4	7
234	Gastric Inhibitory Polypeptide in Newly Diagnosed Ketotic Type I (Insulinâ€”dependent) Diabetics. <i>Acta Medica Scandinavica</i> , 1988, 223, 437-441.	0.0	7

#	ARTICLE	IF	CITATIONS
235	Intestinal sensing and handling of dietary lipids in gastric bypass-operated patients and matched controls. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 28-41.	4.7	7
236	Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 117-125.	2.7	7
237	Effect of Metformin vs. Placebo in Combination with Insulin Analogues on Bone Markers P1NP and CTX in Patients with Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2020, 107, 160-169.	3.1	7
238	Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass. <i>Frontiers in Endocrinology</i> , 2021, 12, 681116.	3.5	7
239	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 75-83.	1.2	7
240	Rapid changes in plasma androgens during insulin withdrawal in male Type 1 (insulin-dependent) diabetics. <i>Journal of Endocrinological Investigation</i> , 1986, 9, 21-25.	3.3	6
241	Heterogeneity of immunoreactive gastric inhibitory polypeptide in the plasma of newly diagnosed type 1 (insulin-dependent) diabetics. <i>European Journal of Endocrinology</i> , 1987, 114, 74-83.	3.7	6
242	Glucose production, oxidation and disposal correlate with plasma lactate levels in HIV-infected patients on HAART. <i>Journal of Infection</i> , 2007, 54, 89-97.	3.3	6
243	Pancreatic β -cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. <i>Regulatory Peptides</i> , 2010, 160, 175-180.	1.9	6
244	Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1164-1168.	2.3	6
245	Metformin monotherapy for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2018, , .	2.8	6
246	Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes. <i>Scientific Reports</i> , 2019, 9, 15154.	3.3	6
247	Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma. <i>Physiological Reports</i> , 2020, 8, e14519.	1.7	6
248	What is Diabetes Remission?. <i>Diabetes Therapy</i> , 2021, 12, 641-646.	2.5	6
249	Effects of a Self-Prepared Carbohydrate-Reduced High-Protein Diet on Cardiovascular Disease Risk Markers in Patients with Type 2 Diabetes. <i>Nutrients</i> , 2021, 13, 1694.	4.1	6
250	Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 77-87.	3.6	6
251	Relation of immunoreactive gastric inhibitory polypeptide to changes in glycaemic control and B cell function in Type 1 (insulin-dependent) diabetes mellitus. <i>European Journal of Endocrinology</i> , 1984, 105, 221-225.	3.7	5
252	Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery. <i>EBioMedicine</i> , 2018, 28, 234-240.	6.1	5

#	ARTICLE	IF	CITATIONS
253	Phosphatidylcholine and its relation to apolipoproteins A-1 and B changes after Roux-en-Y gastric bypass: a cohort study. <i>Lipids in Health and Disease</i> , 2019, 18, 169.	3.0	5
254	Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 243-257.	2.4	5
255	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 242.	3.5	5
256	The effect of DPP-4-protected GLP-1 (7a€“36) on coronary microvascular function in obese adults. <i>IJC Heart and Vasculature</i> , 2019, 22, 139-144.	1.1	5
257	Body weight and metabolic risk factors in patients with type 2 diabetes on a self-selected high-protein low-carbohydrate diet. <i>European Journal of Nutrition</i> , 2021, 60, 4473-4482.	3.9	5
258	Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E443-E452.	3.5	5
259	Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial. <i>Clinical Nutrition</i> , 2022, , .	5.0	5
260	Glycaemic control and weight loss with semaglutide in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 315-317.	11.4	4
261	Relationship between Optimum Miniâ€doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes â€“ A Simulation Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 322-330.	2.5	4
262	No effects of a 6â€week intervention with a glucagonâ€like peptideâ€1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1837-1846.	4.4	4
263	Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity. <i>Journal of the Endocrine Society</i> , 2021, 5, A64-A65.	0.2	4
264	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pumpâ€treated type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 212-220.	4.4	4
265	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. <i>Frontiers in Nutrition</i> , 2022, 9, 889710.	3.7	4
266	Young, low-birth-weight men are not more susceptible to the diabetogenic effects of a prolonged free fatty acid exposure than matched controls. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1398-1406.	3.4	3
267	Sustained lowâ€dose growth hormone therapy optimizes bioactive insulinâ€like growth factorâ€ level and may enhance CD4 Tâ€cell number in HIV infection. <i>Journal of Medical Virology</i> , 2010, 82, 197-205.	5.0	3
268	Relationship Between Two Common Lipoprotein Lipase Variants and the Metabolic Syndrome and Its Individual Components. <i>Metabolic Syndrome and Related Disorders</i> , 2016, 14, 442-448.	1.3	3
269	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 1-45.	0.1	3
270	Metabolic Health in Severely Obese Subjects: A Descriptive Study. <i>Metabolic Syndrome and Related Disorders</i> , 2019, 17, 115-119.	1.3	3

#	ARTICLE	IF	CITATIONS
271	Effects of Roux-en-Y gastric bypass on circulating follistatin, activin A, and peripheral ActRIIB signaling in humans with obesity and type 2 diabetes. <i>International Journal of Obesity</i> , 2021, 45, 316-325.	3.4	3
272	Genetic markers of abdominal obesity and weight loss after gastric bypass surgery. <i>PLoS ONE</i> , 2021, 16, e0252525.	2.5	3
273	The Effect of Bariatric Surgery on Healthcare Costs and Labor Market Attachment. <i>Obesity Surgery</i> , 2022, 32, 998-1004.	2.1	3
274	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypass. <i>Physiological Reports</i> , 2022, 10, e15157.	1.7	3
275	A rapid method for determination of human C-peptide in plasma. <i>Clinica Chimica Acta</i> , 1991, 196, 1-6.	1.1	2
276	Clinical evaluation of a prototype glucose electrode. <i>Biosensors and Bioelectronics</i> , 1992, 7, 683-687.	10.1	2
277	Studies of association of the CASQ1 rs2275703 polymorphism in relation to type 2 diabetes and related quantitative metabolic traits among 7088 Danish whites. <i>Molecular Genetics and Metabolism</i> , 2007, 92, 278-282.	1.1	2
278	Type 2 diabetes: which drug as add-on to metformin?. <i>Lancet, The</i> , 2012, 379, 2222-2223.	13.7	2
279	Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 153-155.	4.4	2
280	Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. <i>Neurogastroenterology and Motility</i> , 2021, , e14210.	3.0	2
281	After Roux-en-Y Gastric Bypass, Enterohepatic Bile Circulation Is Altered and Bile Acid Retention Increased while Bile Acid Homeostasis Remains Normal after Sleeve Gastrectomy. <i>Diabetes</i> , 2018, 67, .	0.6	2
282	Insulin and New Insulin Analogues with Focus on Type 2 Diabetes. , 2007, , 53-65.		2
283	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. <i>BMC Research Notes</i> , 2014, 7, 326.	1.4	1
284	Surgical or medical therapy for patients with obesity and T2DM?. <i>Nature Reviews Endocrinology</i> , 2016, 12, 500-502.	9.6	1
285	Metformin and sulphonylurea (second- or third-generation) combination therapy for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2016, , .	2.8	1
286	Treatment with GLP-1 Receptor Agonists. <i>Endocrinology</i> , 2018, , 571-615.	0.1	1
287	Assessment of Islet Alpha- and Beta-Cell Function. , 2019, , 37-74.		1
288	Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107681.	2.3	1

#	ARTICLE	IF	CITATIONS
289	Follistatin secretion is enhanced by protein, but not glucose or fat ingestion, in obese persons independently of previous gastric bypass surgery. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G753-G758.	3.4	1
290	Dulaglutide for erectile dysfunction in type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 472-473.	11.4	1
291	Fractionated free fatty acids and their relation to diabetes status after Roux-en-Y gastric bypass: A cohort study. <i>Physiological Reports</i> , 2021, 9, e14708.	1.7	1
292	Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. <i>Free Radical Biology and Medicine</i> , 2022, 178, 18-25.	2.9	1
293	β-cell dysfunction and low insulin clearance in insulin-resistant human immunodeficiency virus (HIV)-infected patients with lipodystrophy. <i>Clinical Endocrinology</i> , 2006, 65, 554-554.	2.4	0
294	Treatment of the Metabolic Syndrome by Bariatric Surgery. , 2013, , 191-219.		0
295	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. <i>Metabolomics</i> , 2016, 12, 1.	3.0	0
296	59 - Greater Reductions in HbA1c and Body Weight With Once-Weekly Semaglutide Vs Comparators Across Baseline BMI Subgroups: Posthoc Analysis of SUSTAIN 1 and 7. <i>Canadian Journal of Diabetes</i> , 2020, 44, S25-S26.	0.8	0
297	Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes. <i>European Journal of Case Reports in Internal Medicine</i> , 2021, 8, 002352.	0.4	0
298	Long-term outcomes of dietary carbohydrate restriction for HbA1c reduction in type 2 diabetes mellitus are needed. Reply to Kang J and Ma E [letter]. <i>Diabetologia</i> , 2022, , 1.	6.3	0
299	Title is missing!. , 2020, 15, e0243918.		0
300	Title is missing!. , 2020, 15, e0243918.		0
301	Title is missing!. , 2020, 15, e0243918.		0
302	Title is missing!. , 2020, 15, e0243918.		0
303	Title is missing!. , 2020, 15, e0243918.		0
304	Title is missing!. , 2020, 15, e0243918.		0
305	Early effects of Roux-en-Y gastric bypass on dietary fatty acid absorption and metabolism in people with obesity and normal glucose tolerance. <i>International Journal of Obesity</i> , 2022, 46, 1359-1365.	3.4	0